1. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
- Author
-
Alam H, Tang M, Maitituoheti M, Dhar SS, Kumar M, Han CY, Ambati CR, Amin SB, Gu B, Chen TY, Lin YH, Chen J, Muller FL, Putluri N, Flores ER, DeMayo FJ, Baseler L, Rai K, and Lee MG
- Subjects
- Adenocarcinoma of Lung drug therapy, Adenocarcinoma of Lung metabolism, Animals, Antimetabolites pharmacology, Apoptosis, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Cell Proliferation, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Histones genetics, Histones metabolism, Humans, Lung Neoplasms drug therapy, Lung Neoplasms metabolism, Lung Neoplasms pathology, Mice, Mice, Knockout, Mice, Nude, Mutation, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Period Circadian Proteins genetics, Period Circadian Proteins metabolism, Prognosis, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Adenocarcinoma of Lung pathology, DNA-Binding Proteins antagonists & inhibitors, Deoxyglucose pharmacology, Enhancer Elements, Genetic, Gene Expression Regulation, Neoplastic, Glycolysis, Histone-Lysine N-Methyltransferase physiology, Myeloid-Lymphoid Leukemia Protein physiology, Neoplasm Proteins antagonists & inhibitors
- Abstract
Epigenetic modifiers frequently harbor loss-of-function mutations in lung cancer, but their tumor-suppressive roles are poorly characterized. Histone methyltransferase KMT2D (a COMPASS-like enzyme, also called MLL4) is among the most highly inactivated epigenetic modifiers in lung cancer. Here, we show that lung-specific loss of Kmt2d promotes lung tumorigenesis in mice and upregulates pro-tumorigenic programs, including glycolysis. Pharmacological inhibition of glycolysis preferentially impedes tumorigenicity of human lung cancer cells bearing KMT2D-inactivating mutations. Mechanistically, Kmt2d loss widely impairs epigenomic signals for super-enhancers/enhancers, including the super-enhancer for the circadian rhythm repressor Per2. Loss of Kmt2d decreases expression of PER2, which regulates multiple glycolytic genes. These findings indicate that KMT2D is a lung tumor suppressor and that KMT2D deficiency confers a therapeutic vulnerability to glycolytic inhibitors., Competing Interests: Declaration of Interests The authors declare no competing interests., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF